kras mutation and glutathion What should we know about the 'undruggable' target KRAS? Rerouting the drug response: Overcoming
Rerouting the drug response: Overcoming metabolic adaptation in KRAS mutant cancers Science Signaling KRAS Targeted Therapy Doubles as Component of Immunotherapy NCI Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis Cell Death & Disease Research advances in the treatment of KRAS mutant colorectal cancer from Prof. Guoquan Gao's group at Zhongshan School of Medicine SUN YAT SEN UNIVERSITY The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy PMC
Pay in 4 interest-free payments of $5.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9




